Search
Patexia Community
News and Analysis

Our Members

All »
shailendra Jain
Andrey K
Abhilasha Bora
mike williams
michelle cipolla
Abhinandan Deshmukh
Tima Maslyuchenko
shubham sharma
Mohamed Samir
Elizebeth Maag
Genevieve Victoria Kayat
heta raval
jameswar prusty
Mehdi Sadaghdar
Keemia Kiani

Innovation, Technology, and IP News

The Interplay between Regulatory Exclusivities and Patent Litigation under the Hatch-Waxman Act

The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act, revolutionized the pharmaceutical industry by balancing the interests of...

Objective Evidence in Determining Obviousness

MEDTRONIC, INC. v. TELEFLEX INNOVATIONS Before Moore, Lourie, and Dyk.  Appeal from the Patent Trial and Appeal Board. Summary: A close prima facie case of obviousness can be...

FDA Updates Cybersecurity Guidance

Written by:Matthew Ruth & Philip M. Nelson Going forward, medical device approval will require the device maker to provide cybersecurity information to the...

Patexia Insight 179: Best Patent Litigators of 2023: A Fusion of Analytics and Peer Reviews

In January, we delved into the intricacies of patent litigation in our third annual Patent Litigation Intelligence Report. This comprehensive study spanned five years, from July 1...

Fresh From the Bench: Latest Precedential Patent Case

CASE OF THE WEEK Medtronic, Inc. et al. v. Teleflex Innovations S.A.R.L., Appeal Nos. 2021-2356, -2358, -2361, -2363, and -2365 (Fed. Cir. May 24, 2023) In this week’s Case of...

ANDA Litigation: Navigating the Complexities of Patents and Generic Drug Approvals

In the world of pharmaceuticals, the Abbreviated New Drug Application (ANDA) process plays a critical role in the approval and market entry of generic drugs. However, the intersection...

FDA Approves Qalsody™ for Treatment of ALS

Written by: Douglas W. Crandell, Ph.D. & Robert J. Hilton, Ph.D. On April 25th, 2023, the U.S. Food and Drug Administration (FDA) approved QalsodyTM (tofersen) for the...

Feed tagged as "CBM":
Judge Gilstrap Cautions on Tactics Directed Solely to PTAB Interests
Scott Mckeown Jan 22, 2019
Court Takes Offense to Tactics Geared to PTAB Alone Litigants beware; Judge Rodney Gilstrap (E.D. Texas) warned litigants considered to be using the district... Read More »
Comment: 0 Favorite (0)
Defendant Is Not Estopped from Relying on a Prior Art Reference in District Court that Is Related to a Reference Used in a CBM So Long as the Reference Includes New Disclosure
Knobbe Martens Apr 13, 2018
In Solutran, Inc. v. U.S. Bancorp & Elavon, Inc., No. 13:cv-02637, 2018 WL 1276999 (D. Minn. Mar. 12, 2018), the court denied the plaintiff’s Motion in... Read More »
Comment: 0 Favorite (0)
Post-Institution Disclaimer Insufficient to Avoid CBM Review
Knobbe Martens Jan 25, 2018
The PTAB has determined that a patent owner may not moot a CBM proceeding by disclaiming claims post-institution. Emerson Elect ric Co. v. SIPCO, LLC, CBM2016-00095... Read More »
Comment: 0 Favorite (0)
PTAB Issues New Remand Procedures
Knobbe Martens Nov 20, 2017
On November 16, 2017, the USPTO issued new procedures (“Standard Operating Procedure 9”) for governing cases remanded from the Federal Circuit. These... Read More »
Comment: 0 Favorite (0)
PTAB Denies Institution of CBM Review for Lack of Standing in view of Covenant Not to Sue
Knobbe Martens Sep 27, 2017
Written by Ben J. Everton and David T. Kim The PTAB denied institution of Covered Business Method (CBM) Review, finding that the parties’ license agreement... Read More »
Comment: 0 Favorite (0)
Patent Trial and Appeal Board Activity in the First Five Years+
Knobbe Martens Sep 19, 2017
Written by Peter Law and Kerry S. Taylor, Ph.D. September 16, 2017 marked five years since the Patent Trial and Appeal Board (PTAB) was created.  Some of... Read More »
Comment: 0 Favorite (0)
Federal Circuit Finds Claims Directed to Securing Financing Patent Ineligible
Knobbe Martens Jun 23, 2017
Written by Keith Lim and Vlad Teplitskiy In a precedential opinion, the Federal Circuit affirmed the determination by the Patent Trial and Appeal Board... Read More »
Comment: 0 Favorite (0)
Will Courts Consider Evidence of Patent Eligibility?
Knobbe Martens May 3, 2017
Written by Jeremy Anapol and John M. Carson Patent enforcement by Texas-based DataTreasury Corp. (“DataTreasury”) was a key motivation for the... Read More »
Comment: 0 Favorite (0)
Federal Circuit Limits Scope of Covered Business Method Review
Knobbe Martens Mar 16, 2017
Written by Chang Lim and Lincoln S. Essig The Federal Circuit recently clarified what patents are subject to the Transitional Program for Covered Business Method... Read More »
Comment: 0 Favorite (0)
Fresh from the Bench: Precedential Patent Cases from the Federal Circuit
Peter Heuser Feb 27, 2017
The real news this past week is not from the Circuit but from the Supreme Court’s reversal of the Life Technologies v. Promega case. There, the Supreme Court... Read More »
Comment: 0 Favorite (0)
Covered Business Method Patent: You Keep Using Those Words … We do not Think They Mean What You Think They Means
Bryan Wheelock Feb 22, 2017
In Secure Access, LLC v. PNC BANK NATIONAL ASSOCIATION, [2016-1353] (February 21, 2017), the Federal Circuit vacated the Board’s decision in CBM2014-00100 on... Read More »
Comment: 0 Favorite (0)
A Patent Does Not Become a CBM Patent Because its Practice Could Involve a Potential Sale of a Product or Service
Bryan Wheelock Nov 28, 2016
In Unwired Planet, LLC, v. Google, Inc., [2015-1812] (November 21, 2016) the Federal Circuit vacated and remanded the PTAB’s final written decision in Covered... Read More »
Comment: 0 Favorite (0)
Patexia Insight 17: Is the PTAB Covered Business Method Falling Out of Favor?
Pedram Sameni Oct 26, 2016
Several weeks ago we analyzed the IPR data for Q3 which has been steadily rising since September 2012. This week, our Data Science Team decided to look into Covered... Read More »
Comment: 0 Favorite (0)
PTAB Statistics - Then and Now
Patrick Muffo Aug 16, 2016
The Inter Partes Review (IPR) and Covered Business Method (CBM) procedures were enacted on September 16, 2012. Since then, the PTAB has released data on a monthly... Read More »
Comment: 0 Favorite (0)
Menu